Tom's of Maine $2.9 Million Settlement Over Deceptive Toothpaste Marketing

Tom’s of Maine and its parent company, Colgate-Palmolive, agreed to a $2.9 million class action settlement after consumers alleged that the brand’s toothpaste marketing was deceptive. The claims trace back to concerns raised during an FDA inspection of Tom’s of Maine’s Sanford, Maine manufacturing facility in connection with compliance with the FDA’s Current Good Manufacturing Processes (CGMP)—rules designed to ensure that products are consistently produced and tested to be safe and of appropriate quality. After the inspection, the company reviewed pre-release testing data for thousands of toothpaste batches made between late 2020 and early 2026 and concluded that the batches posed no safety risk to consumers, but multiple lawsuits were still filed nationwide and were consolidated for settlement in federal court (U.S. District Court for the Eastern District of New York). The lawsuit’s significance is practical for consumers: it covers buyers of Tom’s of Maine toothpaste from November 21, 2020 through March 6, 2026, including a relatively “easy” claim option where you can receive an average value for one product per household without providing proof of purchase (you attest to having bought the product). Alternatively, those with receipts or purchase records may claim refunds for up to three products. Tom’s and Colgate deny wrongdoing or liability and say they did not misrepresent facts, but the settlement helps them avoid the cost and uncertainty of continuing litigation—while class members receive a defined, court-approved path to payment ahead of the July 6, 2026 claim deadline. Broader implications are that this case fits a wider pattern of “consumer deception” class actions tied to food, drug, and health-adjacent products—areas where FDA oversight and CGMP compliance matter, and where marketing claims can be scrutinized even when companies maintain that product safety was not compromised. Similar cases often involve consolidated complaints, “no proof required” reimbursement structures (especially when proof burdens could exclude many buyers), and settlement administration that may reduce individual payments if claims exceed available funds, with remaining money sometimes donated to nonprofit causes.